Boston, Jan. 15, 2026 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Immunotherapy Drugs: Global Markets” is expected to grow from $260.7 billion in 2025 to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
This report analyzes the global immunotherapy drug market, covering current trends, market estimates, and projected growth. It segments the market by therapy type, which includes checkpoint inhibitors, monoclonal antibodies and cytokine therapy. The three types of mAbs covered are naked mAbs, conjugated mAbs and bispecific mAbs). The report also segments the market by application into cancer, autoimmune, and chronic inflammatory diseases. Regions covered are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America, with country level data also included. The report also explores the regulatory landscape, key market drivers, restraints, opportunities, competitive dynamics, and the market shares of leading companies, in order to forecast industry growth and identify these factors’ long- term impacts on the immunotherapy market.
This report is relevant now because immunotherapy drugs are experiencing rapid growth and innovation, reshaping the treatment of disease. With new drug approvals and expanding therapeutic indications, understanding these advances is critical for clinicians, researchers, and pharmaceutical stakeholders. The report provides insights into the dynamic market forces driving this transformation.
The factors driving the market’s growth include:
Increasing Incidence of Chronic Diseases: The global rise in chronic illnesses like cancer and autoimmune disorders is driving demand for immunotherapy. These therapies offer targeted treatment options.
R&D Spending by Leading Companies: Investments in R&D by pharmaceutical and biotech firms accelerates clinical trials and the launch of advanced immunotherapy drugs.
Government Funding: Governments worldwide are increasing funding for cancer research and immunotherapy. Grants and partnerships help overcome high development costs and support faster commercialization.
Technological Advances in Immunotherapy: Innovations such as CAR-T cell therapy, checkpoint inhibitors, and mAbs are transforming treatment. Advances in genomics and AI enable more precise and effective therapies.
Potential in Immunotherapy: Immunotherapy offers long-term benefits and fewer side effects compared to traditional treatments. Its adaptability for personalized medicine and expanding applications highlights its future growth potential.
Request a sample copy of the global immunotherapy drugs market report.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2024 |
| Forecast period considered | 2025-2030 |
| Base year market size | $235.8 billion |
| Market size forecast | $467.4 billion |
| Growth rate | CAGR of 12.4% for the forecast period of 2025-2030 |
| Segments covered | Therapy Type, Application, and Region |
| Regions covered | North America, Europe, Asia-Pacific, MEA, and South America |
| Countries covered | U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, China, India, Japan, South Korea, Australia, Brazil Argentina, Middle East, and Africa |
| Market drivers |
|
Interesting facts:
- Unlike chemotherapy, immunotherapy drugs work by mobilizing the immune system to recognize and destroy cancer cells. These treatments can have long-lasting effects, sometimes for years, as they create an "immune memory" that continues to fight cancer even after treatment ends.
- However, immunotherapy can sometimes lead to tumor growth, a phenomenon known as pseudoprogression. In addition, the activation of immune memory may cause the immune system to mistakenly attack healthy tissues.
The report addresses the following questions:
- What are the projected size and growth rate of the market?
- The global market for immunotherapy drugs was valued at $235.8 billion in 2024 and is projected to reach $467.4 billion by the end of 2030. The market is expected to grow at a CAGR of 12.4% during the forecast period.
- What factors are driving the growth of the market?
- The driving factors are the rising cases of chronic diseases, increasing R&D spending and the rise in government funding.
- What are the market’s restraints?
- The restraints include high cost of immunotherapy drugs, rising competition from generics, and the lack of skilled professionals.
- Which market segments are covered in the report?
- The market in this report is segmented into immunotherapy type, checkpoint inhibitors, mAbs, and cytokine therapy, with mAbs sub-segmented into naked, conjugated and bispecific monoclonal antibodies. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1), and lymphocyte activation gene 3 (LAG-3). The application segment is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.
- Which therapy type will be dominant through 2030?
- The dominant therapy type will be mAbs.
- Which region has the largest market share?
- North American had the largest market share in 2024, share valued at $131.3 billion and projected to reach $262.8 billion by the end of 2030, at a CAGR of 12.6% during the forecast period.
Market leaders include:
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GSK PLC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO.INC.
- NOVARTIS AG
- PFIZER INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Related report include:
Global Markets for Allergy Diagnostics and Treatments: The report provides a comprehensive analysis of the global allergy diagnostics and treatment market, covering market trends, regulatory factors, drivers, restraints, and opportunities. It examines diagnostics such as skin and blood tests and treatments including antihistamines, corticosteroids, immunotherapy, and others. Treatments are segmented by allergen type and drug type, while regional analysis spans North America, Europe, Asia Pacific, MEA, and South America. The report also highlights the market potential and competitive landscape with key player insights.
Biologic Therapeutic Drugs: Technologies and Global Markets: The report provides a comprehensive overview of the global biologic therapeutic drug market, analyzing trends, drivers, challenges, and emerging technologies. It segments the market by product type (monoclonal antibodies, vaccines, peptide hormones, cell and gene therapies), source (mammalian, microbial, others), and application (oncology, autoimmune, infectious diseases). Regional coverage includes North America, Europe, Asia-Pacific, MEA and South America, with insights into specific countries’ markets. The study also examines the market share rankings of leading companies, well as their financials, product portfolios, and recent developments.
Purchase a copy of the report direct from BCC Research.
For further information or to make a purchase, please contact with info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, U.S. Email: info@bccresearch.com Phone: +1 781-489-7301
